Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Emily Curran, Wendy Stock

Blood 2019 Apr 18

filter terms:

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL. © 2019 by The American Society of Hematology.